3Z Pharmaceuticals, a CNS-focused therapeutic development specialist, today announced the publication of a groundbreaking study in The Journal of Pharmacology and Experimental Therapeutics, unveiling novel insights into the metabolic mechanisms of ADHD treatments. This research, utilizing untargeted metabolomic and lipidomic profiling, addresses a critical knowledge gap in ADHD treatment. It reveals a convergence of molecular pathways among stimulant and non-stimulant ADHD medications and supports 3Z’s earlier announced discovery of amlodipine as an L-type calcium channel blocker candidate.
ADHD is a highly prevalent neurodevelopmental disorder with complex underlying mechanisms and limited treatment options. While both stimulant and non-stimulant medications are widely used, their precise metabolic effects on the brain remain poorly understood.
